Office-use compounding in Alaska

What the rule requires in practice

Each item carries a confidence level. Verbatim rule text is high confidence; a reading of how two provisions interact, or a source that could not be re-verified, is not.

The operative rule is not published online by the state, and that is the headlineHigh confidence

Alaska is the only entry in this file whose governing compounding text the state does not put on the internet. The Administrative Code adopts a Board of Pharmacy pamphlet by reference, and the compilation’s own editor’s note tells you how to get it: from the Division of Corporations, Business and Professional Licensing at the State Office Building, 9th Floor, 333 Willoughby Avenue, Juneau, with a phone number. That is the state’s official pointer. This page cites the one copy that can actually be opened — the Division’s combined statutes-and-regulations compilation, in which the pamphlet is reproduced in full.

The incorporation chain, so you can check it end to endHigh confidence

The pamphlet is made binding by 12 AAC 52.440, which is authorised by AS 08.80.030 and AS 08.80.157. The rule’s own history line reads "(Eff. 1/16/98, Register 145; am 10/9/2008, Register 188)" — so it has adopted this same February 2008 document for the whole of its current life. It is in force. It has not been repealed and it has not been superseded.

A title mismatch that defeats a literal searchHigh confidence

The rule incorporates a pamphlet "titled, ‘Compounding Practices,’" and the editor’s note uses the same words. The document’s own printed heading is GOOD COMPOUNDING PRACTICES. Searching for the title the rule gives you will not find the document the rule means, which is a small part of why this provision is so rarely reported.

The ceiling is a relationship and a history, not a numberHigh confidence

There is no percentage and no unit cap on office-use supply in Alaska. Two limits do the work instead. Anticipatory compounding is capped at the amount for which the pharmacist has a historical basis of valid prescription drug orders inside an established pharmacist–patient–practitioner relationship, and going above it is manufacturing. And supply to practitioners in inordinate amounts, or without that relationship, is manufacturing too. Both ceilings are qualitative, which makes them harder to plan against than a percentage, not easier.

Alaska adopts no USP compounding chapterHigh confidence

The entire sterile rule is one sentence: a pharmacy or pharmacist preparing or dispensing sterile pharmaceuticals shall adhere to the accepted standard of care. No USP general chapter is adopted anywhere in the pharmacy code — not 795, not 797, not 800. So there is no sterility split on the permission, and no compendial standard to point at either.Stated as "no chapter is adopted" rather than as a hit count on purpose: the string 800 does occur in the chapter, four times, and every occurrence is a self-reference to 12 AAC 52.800, the drug-room section. A reader checking the negative with a naive search will find those and should not mistake them for USP 800.

The five per cent rule and the compounding rule agree here, which is rareHigh confidence

Alaska exempts from the wholesale-distributor licence transfers whose gross dollar value does not exceed five per cent of the total prescription drug sales revenue of either party in any rolling twelve-month period — and its limbs name a practitioner outright, on both the selling and the buying side. Almost everywhere else in this file the percentage clause and the compounding rule contradict each other. In Alaska they point the same way. Say it precisely, though: the authority to compound for this purpose comes from the pamphlet, not from the exemption, which only decides whether a wholesale licence is owed.

The exemption’s biggest hazard is one undefined wordMedium confidence

Its limbs say "retail pharmacy", not "pharmacy", and the term is never defined anywhere in the pharmacy statutes or the pharmacy code. If a compounding-only or mail-order pharmacy is not a retail pharmacy, the exemption is simply unavailable to it and every supply to a practitioner — at any value — needs a wholesale drug distributor licence. There is also a grammatical question in the denominator: under a negative, "does not exceed five percent of either the transferor or transferee" most naturally means neither may be exceeded, so both limits bind. Model the strict reading of both points.

What the statute treats as manufacturing, and why it matters hereHigh confidence

The statutory definition puts the line at resale: manufacturing includes preparing and promoting commercially available products from bulk compounds for resale by pharmacies, practitioners or other persons. That is the same shape as the pamphlet’s own exception, which bars offering compounded products to practitioners for resale and then carves out supply for the practitioner to administer. Administration is the permitted end use; onward sale is the line.

No label legend exists for office stockHigh confidence

The labelling rule opens by applying to every container in which a prescription drug order is dispensed, and its elements include the patient’s name and the order’s identification number. Non-patient-specific stock has neither, and Alaska has written no separate legend for it. There is nothing to comply with and nothing to report.

Last change, and the risk that has no date on itHigh confidence

The incorporating rule was last amended in October 2008 and the pamphlet is frozen at February 2008. The structural risk is unusual and worth naming: if the Board ever republishes or replaces that pamphlet, Alaska’s whole office-use answer changes while the text of 12 AAC 52.440 stays identical. There would be no visible change in the code at all.

Alaska at a glance

Receiving 503B office stock in Alaska

Alaska licenses outsourcing facilities under that name, with a dedicated rule and its own fee, and the Board of Pharmacy is the licensor rather than an advisory body. The receiving practice needs nothing, and the reason is written into the statute. The interesting part is a barrier that runs the opposite way from every other jurisdiction here.

Everything above this heading answers the supply question: may a state-licensed 503A pharmacy ship non-patient-specific stock? This section answers the other half. Registration with FDA under section 503B is a federal exemption from federal law and preempts no state licensing scheme, so it is never the whole answer on its own — a state credential is the norm rather than the exception, it is not always issued by the board of pharmacy, and in some states the category you would search for does not exist. What Alaska asks for is set out below, including where we could not establish it.

What the 503B must hold to ship inHigh confidence

An Alaska outsourcing facility licence. Alaska uses the federal term verbatim, defines it in statute and gives it its own rule: registration with the FDA as an outsourcing facility, compliance with 21 U.S.C. 353b, a named designated representative, an attestation of a self-inspection within the last two years, and — unusually — the results of the facility’s most recent FDA Good Manufacturing Practice inspection. The fee is $100 on application plus $550 biennially, per location.Alaska substitutes a federal inspection for one of its own here, which is worth knowing if your facility’s last FDA inspection did not go well: the state asks to see it.

Does your practice need a permit?High confidence

No, and the statute says so in terms: the facility-licensing section does not apply to the offices of physicians, osteopaths, podiatrists, physician assistants, advanced nurse practitioners, dentists, veterinarians, dispensing opticians or optometrists. The duty runs the other way — a wholesale distributor shipping into Alaska must first verify that its purchaser holds a valid licence under AS 08 to supply the drug within the scope of that purchaser’s practice. Your professional licence is the credential your supplier has to check.

Administer vs dispenseHigh confidence

The permission is written for administration and stops there: supply is permitted for a prescribing practitioner to administer to an individual patient. Handing stock to a patient to take away is the resale-shaped conduct the same sentence bars, and the statutory manufacturing definition points the same way by putting its line at resale.

Scheduled (controlled) stockHigh confidence

Alaska has no state controlled-substance registration to obtain because it repealed its own and adopted the federal one in its place — a position it shares with Wisconsin, Kentucky and others here, though its route there is its own. Alaska had its own scheme and repealed it in 1986, adopting the federal one in its place by statute — so the DEA registration is the Alaska registration, as a matter of Alaska law. A separate person-level registration with the prescription drug monitoring programme is still mandatory, at a fee of $0. State all three facts together; any two of them alone give the wrong impression.

How to check a facility’s credential before you order is set out in how to place an office-use order.

What this page does not establish

• The single most important thing to know about researching Alaska is that its governing compounding text is not on the internet. If you check this page against the Alaska Statutes and the Administrative Code you will not find the permission, and you may reasonably conclude we invented it. We did not: it is in the Board of Pharmacy pamphlet the Code adopts by reference, reproduced inside the Division’s combined compilation, which is what this page cites and what a reader can open.
• One half of Alaska’s answer is deliberately left open. The pamphlet’s paragraph on compounding commercially available products from bulk is patient-specific by its own terms, requiring the practitioner to have prescribed the compounded product for that prescription and the patient to have been told a pharmacist will prepare it. Whether office stock of a compounded equivalent of a commercially available product is inside the permission or outside it is genuinely unsettled on the text, and the Board has published no reading anyone can reach. This page publishes the permission and stops short of that question.
• Whether "retail pharmacy" in the five per cent exemption reaches a compounding-only or mail-order pharmacy is not established. The term is used repeatedly and defined nowhere. If it does not reach yours, the exemption is unavailable and a wholesale drug distributor licence is owed on any supply to a practitioner, at any value.
• A structural point about nonresident supply that sits where nobody looks. The pharmacy application rule requires a pharmacy to give the active ALASKA licence number of its pharmacist-in-charge, while asking for other pharmacists’ licence numbers only in their current jurisdiction. The outsourcing facility rule asks for a designated representative and no Alaska credential at all. On the face of those rules the barrier falls on the pharmacy route and not on the outsourcing facility route — the reverse of the pattern elsewhere in this file. It is a reading of two application rules, not a Board ruling.
• The Board of Pharmacy’s own interpretive material — newsletters, FAQs, declaratory rulings, minutes and proposed-regulation packets — could not be reached at all. The Division’s site refused every client tried, including a real browser. A single board FAQ could move this page in either direction, and none of it has been read.
• We searched no case law, attorney-general opinions or disciplinary orders for this state, and search engines were unavailable when it was researched. Read nothing into that silence — it means we have not looked, not that nothing is there.